Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MELA Sciences to Report Second Quarter Financial Results on Thursday, August 13

SSKN

Conference Call to Follow at 4:30 p.m. EDT

HORSHAM, Pa., Aug. 12, 2015 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, will release second quarter financial results on Thursday, August 13, after the market close. MELA Sciences President and Chief Executive Officer, Michael Stewart, and Robert W. Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.

Conference Call Details:
Date: Thursday, August 13
Time: 4:30pm Eastern Time
Toll Free: 888-337-8169
International: 719-457-2689
Passcode: 3537662
Webcast: http://public.viavid.com/player/index.php?id=115368
   
Replays, available through August 27, 2015
Toll Free: 877-870-5176
International: 858-384-5517
Replay PIN: 3537662

About MELA Sciences, Inc. (www.melasciences.com)

MELA Sciences is a medical technology company focused on the dermatology market. Through its acquisition of the XTRAC and VTRAC businesses, MELA Sciences markets those products for the treatment of psoriasis, vitiligo and other skin conditions. The Company is also in the early commercialization stages of the MelaFind® system, an innovative software-driven technology that provides additional information to dermatologists in the management of melanoma skin cancer.

CONTACT: Investor Contacts:
         Robert W. Cook
         MELA Sciences, Inc.
         914-373-6936
         rcook@melasciences.com
         
         Andrew McDonald
         LifeSci Advisors, LLC
         646-597-6987
         Andrew@LifeSciAdvisors.com


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today